BCAL Diagnostics LimitedASX: BDX

BCAL Seeks Board Change at Genetic Signatures

Sep 2, 2026 at 10:40 PM EDT · Issued by BCAL Diagnostics Limited via ASX

Filed with ASX · Sep 2, 2026 at 10:40 PM EDT

On 6ix: 6ix.com/news/bcal-seeks-board-change-at-genetic-signatures

BCAL Diagnostics Limited ABN 51 142 051 223 Suite 506 Level 5 50 Clarence Street Sydney NSW 2000 ASX Announcement 3 September 2026 BCAL Diagnostics seeks board change at Genetic Signatures Highlights - BCAL Diagnostics has given a s249D notice to Genetic Signatures seeking...

View Attachment

6ix hasn’t read this filing yet.

BCAL Diagnostics Limited on 6ix

Story so far

BCAL Takes Interest in Genetic Signatures to 18.46%Aug 25, 2026
Change in Substantial Shareholder Notice for GSSAug 25, 2026
BCAL to Acquire Shares in Genetic SignaturesJul 2, 2026

Earlier from BCAL Diagnostics

Investor Presentation September 2026Sep 2
Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PMAug 31
Appendix 4E and Annual Report to shareholdersAug 28
Appendix 4G and Corporate Governance StatementAug 28
BCAL Takes Interest in Genetic Signatures to 18.46%Aug 25

Later from BCAL Diagnostics

Clarification of BCAL's Position in Relation to GSSSep 9
Notice of Annual General Meeting/Proxy FormSep 17
Letter to Shareholders re Annual General MeetingSep 17
BCAL Introduces Avantect Multi-Cancer Early Detection TestSep 22
BREASTESTplus 2 clinically validatedSep 29

All BCAL Diagnostics news releases

Follow BCAL Diagnostics into a list and get an email when it puts out news.

Follow BCAL Diagnostics